Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:TVTX
DatumZeitQuelleÜberschriftSymbolFirma
31/10/202413h41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TVTXTravere Therapeutics Inc
31/10/202413h36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
31/10/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
31/10/202412h00GlobeNewswire Inc.Travere Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
26/10/202413h01GlobeNewswire Inc.Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024NASDAQ:TVTXTravere Therapeutics Inc
21/10/202422h30GlobeNewswire Inc.Travere Therapeutics to Report Third Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
17/10/202413h01GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
17/10/202408h30PR Newswire (Canada)CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
17/10/202408h30PR Newswire (US)CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
17/10/202408h30PR Newswire (US)CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
14/10/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024NASDAQ:TVTXTravere Therapeutics Inc
01/10/202402h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
30/09/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
26/09/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
26/09/202422h01GlobeNewswire Inc.Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-UpNASDAQ:TVTXTravere Therapeutics Inc
12/09/202423h00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
12/09/202400h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202422h01GlobeNewswire Inc.Travere Therapeutics to Present at the 2024 Cantor Global Healthcare ConferenceNASDAQ:TVTXTravere Therapeutics Inc
10/09/202403h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202403h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202403h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202403h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
10/09/202403h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
09/09/202416h35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
09/09/202416h34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
06/09/202403h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
05/09/202423h34GlobeNewswire Inc.Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
22/08/202422h30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024NASDAQ:TVTXTravere Therapeutics Inc
06/08/202422h30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TVTX